These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1113 related articles for article (PubMed ID: 8769713)

  • 21. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
    Xiang J; Moyana T
    Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An optimum anti-melanoma response in mice immunized with fibroblasts transfected with DNA from mouse melanoma cells requires the expression of both syngeneic and allogeneic MHC-determinants.
    de Zoeten EF; Markovic D; Cohen EP
    Gene Ther; 2002 Sep; 9(17):1163-72. PubMed ID: 12170380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.
    Herkel J; Jagemann B; Wiegard C; Lazaro JF; Lueth S; Kanzler S; Blessing M; Schmitt E; Lohse AW
    Hepatology; 2003 May; 37(5):1079-85. PubMed ID: 12717388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Th cells and Th2 responses can develop in the absence of MHC class II-CD4 interactions.
    Wack A; Corbella P; Harker N; Roderick K; Norton T; Williams K; Williams O; Kioussis D
    J Immunol; 1999 Aug; 163(3):1162-9. PubMed ID: 10415010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
    Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.
    Hermans IF; Ritchie DS; Daish A; Yang J; Kehry MR; Ronchese F
    J Immunol; 1999 Jul; 163(1):77-81. PubMed ID: 10384102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth.
    Campbell I; Moyana T; Carlsen S; Zheng C; Xiang J
    Cancer Gene Ther; 2000 Jan; 7(1):37-44. PubMed ID: 10678354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
    Marzo AL; Lake RA; Robinson BW; Scott B
    Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells.
    Diebold SS; Cotten M; Koch N; Zenke M
    Gene Ther; 2001 Mar; 8(6):487-93. PubMed ID: 11313828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
    Grangeon C; Cormary C; Douin-Echinard V; Favre G; Couderc B; Tilkin-Mariamé AF
    Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
    Zeng G
    J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New strategies of mammary cancer vaccination.
    Accolla RS; Frangione V; De Lerma Barbaro A; Mortara L
    Breast J; 2010; 16 Suppl 1():S42-4. PubMed ID: 21050309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Murine neuroblastoma vaccines produced by retroviral transfer of MHC class II genes.
    Hock RA; Reynolds BD; Tucker-McClung CL; Heuer JG
    Cancer Gene Ther; 1996; 3(5):314-20. PubMed ID: 8894250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen.
    Hess AD; Thoburn C; Chen W; Miura Y; Van der Wall E
    Clin Immunol; 2001 Oct; 101(1):67-76. PubMed ID: 11580228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
    Bonehill A; Heirman C; Thielemans K
    J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.